UPBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Upstream Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$2.80+0.04 (+1.45%)
Close on Oct 19, 2026
- Market cap
- $152.79M
- P/E (TTM)
- –
- Dividend yield
- –
Upstream Bio statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Upstream Bio | Industry median |
|---|---|---|
| Market Cap | $153.36M | $197.05M |
| Enterprise Value | -$107.95M | $106.56M |
| PS Ratio | 48.56 | 3.93 |
| PB Ratio | 0.57 | 2.14 |
| P/TBV Ratio | 0.57 | 2.46 |
Enterprise value
| Measure | Upstream Bio | Industry median |
|---|---|---|
| EV / Sales | -34.18 | 2.69 |
Income (trailing twelve months)
| Measure | Upstream Bio | Industry median |
|---|---|---|
| Revenue | $3.16M | $57.94M |
| Operating Income | -$169.98M | -$21.44M |
| Net Income | -$156.50M | -$22.46M |
| EBITDA | -$169.78M | -$16.91M |
| EPS (Diluted) | -$2.89 | -$0.83 |
Margins
| Measure | Upstream Bio | Industry median |
|---|---|---|
| Operating Margin | -5382.7% | -44.5% |
| Profit Margin | -4955.7% | -39.2% |
| EBITDA Margin | -5376.3% | -31.3% |
Returns
| Measure | Upstream Bio | Industry median |
|---|---|---|
| Return on Equity (ROE) | -46.0% | -53.1% |
| Return on Assets (ROA) | -44.6% | -41.0% |
| Return on Invested Capital (ROIC) | -1082.4% | -32.0% |
| Return on Capital Employed (ROCE) | -62.7% | -37.8% |
Growth
| Measure | Upstream Bio | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 16.0% | 6.01% |
Balance sheet
| Measure | Upstream Bio | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $261.31M | $62.42M |
| Net Cash (Debt) | $261.31M | $15.68M |
| Net Cash Per Share | $4.77 | $0.65 |
| Equity (Book Value) | $270.96M | $48.79M |
| Book Value Per Share | $4.95 | $1.36 |
| Tangible Book Value | $270.96M | $23.06M |
| Working Capital | $269.61M | $75.77M |
Financial position
| Measure | Upstream Bio | Industry median |
|---|---|---|
| Current Ratio | 27.99 | 3.30 |
| Quick Ratio | 26.24 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Upstream Bio | Industry median |
|---|---|---|
| Operating Cash Flow | -$136.34M | -$12.35M |
Efficiency
| Measure | Upstream Bio | Industry median |
|---|---|---|
| Asset Turnover | 0.01 | 0.38 |
| Revenue Per Employee | $42.11K | $398.96K |
| Profits Per Employee | -$2.09M | -$732.08K |
| Employee Count | 75 | 73 |
Dividends and yields
| Measure | Upstream Bio | Industry median |
|---|---|---|
| Earnings Yield | -102.0% | -21.2% |
Shares
| Measure | Upstream Bio | Industry median |
|---|---|---|
| Shares Outstanding | 54,771,000 | 59,128,900 |
| Shares Change (QoQ) | 0.65% | 0.54% |
| Float | 44,554,300 | 48,744,500 |
| Shares Held by Insiders | 18.7% | 11.8% |
| Shares Held by Institutions | 92.3% | 59.4% |
Taxes
| Measure | Upstream Bio | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
Scores
| Measure | Upstream Bio | Industry median |
|---|---|---|
| Altman Z-Score | 6.11 | 0.10 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Upstream Bio's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.